Science AI Journal
Medicine · Research topic

Open research questions in Prostate Cancer Treatment and Research

223 unresolved questions extracted from the limitations and future-work sections of 635 Prostate Cancer Treatment and Research papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Further investigation of the role of AS in PCa, - Exploration of the potential of AS as a biomarker for PCa prognosis

    Prognostic alternative mRNA splicing signature and immune infiltration in prostate cancer · 2026 · DOI

  • The paper identifies a gap in understanding the correlation between AS events and overall survival in prostate cancer patients. The study aims to address this gap by exploring the AS milieu in tumors to identify biological markers with high prognostic significance.

    Prognostic alternative mRNA splicing signature and immune infiltration in prostate cancer · 2026 · DOI

  • Further research is needed to evaluate the cost-effectiveness of medical ADT compared to surgical ADT in different settings, - Research on the long-term effects of medical ADT and surgical ADT on patients with advanced prostate cancer is needed

    The cost-effectiveness of medical versus surgical androgen deprivation therapy for advanced prostate cancer in Tanzania: a Markov model-based analysis · 2026 · DOI

  • The study identifies a need to evaluate the cost-effectiveness of medical androgen deprivation therapy compared to surgical androgen deprivation therapy in Tanzania. There is a gap in knowledge about the cost-effectiveness of these treatments in limited resource settings.

    The cost-effectiveness of medical versus surgical androgen deprivation therapy for advanced prostate cancer in Tanzania: a Markov model-based analysis · 2026 · DOI

  • The paper identifies technical limitations in the clinical translation of spatial transcriptomics in metastatic castration-resistant prostate cancer. The authors note the challenge of integrating the spatial architecture of the tumor microenvironment into routine clinical trial design. The paper highlights the need for further research to overcome the ecological drivers of resistance.

    Tumor‑immune spatiotemporal co‑evolution: A new paradigm for understanding and overcoming therapy resistance in metastatic castration‑resistant prostate cancer (Review) · 2026 · DOI

  • The paper identifies a gap in the current understanding of the mechanisms driving therapy resistance in metastatic castration-resistant prostate cancer. The authors highlight the need for a comprehensive understanding of the ecological drivers of resistance. The paper notes that prior work has not fully considered the spatial and temporal dynamics of the immune ecosystem.

    Tumor‑immune spatiotemporal co‑evolution: A new paradigm for understanding and overcoming therapy resistance in metastatic castration‑resistant prostate cancer (Review) · 2026 · DOI

  • Investigation into the molecular basis for tissue selectivity, - Development of SARMs with estrogenic activity, - Head-to-head trials comparing SARMs to conventional androgens, - Research into the long-term effects of SARMs

    Selective androgen receptor modulators: a critical appraisal · 2025 · DOI

  • The gap in understanding SARMs' tissue selectivity and their potential clinical applications. The lack of head-to-head trials with conventional androgens. The need for further research on the molecular mechanisms underlying SARMs' effects.

    Selective androgen receptor modulators: a critical appraisal · 2025 · DOI

  • Despite the negative regulation of E-cadherin expression by Rac1, the loss of Rac1 was insufficient to reverse the mesenchymal phenotype typical of AR-null PCa cells.

    RAC1 signaling in prostate cancer: VAV GEFs take center stage · 2025 · DOI

  • Identifying the GEF(s) responsible for Rac activation in any given model is daunting due to limited knowledge about the spatial and temporal expression of individual members of the large Rac-GEF family and their activation statuses.

    RAC1 signaling in prostate cancer: VAV GEFs take center stage · 2025 · DOI

  • Background: Prostate cancer demonstrates significant metabolic heterogeneity, but its role in therapeutic resistance and disease progression remains unclear.

    Metabolic subtyping reveals PDIK1L as a dual-functional regulator of progression and PARP inhibitor sensitivity in prostate cancer · 2025 · DOI

  • The AR/AR-V7 protein is regulated by the E3 ubiquitin ligase STUB1 and a complex involving HSP70, but the precise mechanism remains unclear.

    A novel peptide encoded by circSRCAP confers resistance to enzalutamide by inhibiting the ubiquitin-dependent degradation of AR-V7 in castration-resistant prostate cancer · 2025 · DOI

  • Further research into the underlying biological mechanisms is needed, highlighting the need for safe, targeted therapeutic approaches in PCa treatment.

    Advancing prostate cancer research: an exploration of periprostatic adipose stem cells · 2025 · DOI

  • While ASCs within PPAT influence the tumor stroma, the mechanisms behind their interactions with PCa cells are not fully understood, with studies reporting both inhibitory and promoting effects on cancer progression.

    Advancing prostate cancer research: an exploration of periprostatic adipose stem cells · 2025 · DOI

  • Future studies are required to further characterize the clinical utility of further treatment intensification among men with mHSPC for whom ADT plus enzalutamide fails to achieve undetectable PSA.

    Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer · 2025 · DOI

  • Non-Hispanic Black men are poorly represented in precision oncology cohorts, and therefore differences in alterations frequencies between non-Hispanic Black and White men remain poorly characterized.

    Somatic Tumor Next-Generation Sequencing in US Veterans With Metastatic Prostate Cancer · 2025 · DOI

  • Finally, a public epigenomic resource was generated using a distinct chromatin marker that has not been widely investigated in prostate cancer.

    Plasma Cell–Free DNA Chromatin Immunoprecipitation Profiling Depicts Phenotypic and Clinical Heterogeneity in Advanced Prostate Cancer · 2024 · DOI

  • Although many known genetic alterations can predispose tumors to acquiring the NEPC phenotype, it remains unclear what, if any, drivers are essential to this progression.

    ASCL1 Drives the Development of Neuroendocrine Prostate Cancer · 2024 · DOI

  • Nevertheless, our knowledge of NTD structure has been limited to the primary sequence of amino acid chain and a few secondary structure motif, acting as a barrier for computational and pharmaceutical analysis to decipher dynamic conformation and drug-target interaction.

    N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review · 2024 · DOI

  • However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules, varies in the process of lineage plasticity, wherein tumor cells alter their identity and acquire new oncogenic properties.

    Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen–targeted therapies · 2024 · DOI

  • How inflammation contributes to prostate enlargement and/or BPH symptoms and the underlying mechanisms remain unclear.

    Inflammation impacts androgen receptor signaling in basal prostate stem cells through interleukin 1 receptor antagonist · 2024 · DOI

  • INTRODUCTION: Visceral metastasis is an important predictor for poor outcomes in prostate cancer, however, the prognostic significance surrounding the specific sites of visceral metastasis remains unclear.

    Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients · 2024 · DOI

  • The molecular mechanisms driving the onset and metastasis of prostate cancer remain poorly understood.

    Role of actin-binding proteins in prostate cancer · 2024 · DOI

  • The use of androgen receptor pathway inhibitors (ARPIs) has led to an increase in the proportion of AR-null prostate cancer, including neuroendocrine prostate cancer (NEPC) and double-negative prostate cancer (DNPC), but the mechanism underlying this lineage transition has not been elucidated.

    ID2 Promotes Lineage Transition of Prostate Cancer through FGFR and JAK-STAT Signaling · 2024 · DOI

  • However, the agent that is more effective against nonmetastatic CRPC remains unclear.

    Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa · 2024 · DOI

Most-cited papers in Prostate Cancer Treatment and Research

Most recent work

Find a gap in your own Prostate Cancer Treatment and Research sub-topic

This page shows what the Prostate Cancer Treatment and Research literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
2,044 open questions
Substance Abuse Treatment and Outcomes
1,964 open questions
Smoking Behavior and Cessation
990 open questions
Dementia and Cognitive Impairment Research
974 open questions
Innovations in Medical Education
960 open questions
Physical Activity and Health
923 open questions
Attention Deficit Hyperactivity Disorder
839 open questions
Schizophrenia research and treatment
709 open questions
223 open questions have been extracted from the limitations and future-work passages of 635 Prostate Cancer Treatment and Research papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.